AAAAI 2022: Ligelizumab May Confer Chronic Spontaneous Urticaria Patients With Angioedema the Same Quality of Life as Those Without Angioedema
Benefits of this investigational drug do not appear to be influenced by levels of baseline basophil histamine release
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.